You are here: Industry Insights > Tecentriq

News List

Roche announces positive results of lung cancer drug Tecentriq biospectrumasia
July 05, 2018
The combination of Tecentriq plus chemotherapy Abraxane, as an initial (first-line) treatment, significantly reduced the risk of disease
With latest data, has Roche's Tecentriq found a blockbuster lung cancer niche? fiercepharma
June 26, 2018
So far, Roche’s Tecentriq hasn’t been able to find a piece of the lung cancer market to call its own. But that may change after its latest trial win.
Roche says first-line Tecentriq combination meets main goals in Phase III non-squamous NSCLC study firstwordpharma
May 30, 2018
Roche announced Phase III results Tuesday showing that patients with advanced non-squamous non-small-cell lung cancer (NSCLC) who took the company's PD-L1 inhibitor Tecentriq (atezolizumab) plus chemotherapy as a first-line treatment achieved significantl
Merck's Keytruda, Roche's Tecentriq may lag chemo in some cancer patients, FDA says fiercepharma
May 23, 2018
Merck and Roche’s immunotherapies are each approved solo for certain previously untreated bladder cancer patients. But for other frontline patients, the drugs may be hurting their survival chances.
TECENTRIQ, COTELLIC Did Not Meet Primary Endpoint americanpharmaceuticalreview
May 18, 2018
Genentech announced the Phase III IMblaze370 study evaluating the combination of TECENTRIQ (atezolizumab) and COTELLIC (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib.
Roche’s Tecentriq halts disease in squamous lung cancer pharmaphorum
March 21, 2018
Roche’s cancer immunotherapy Tecentriq has produced strong results which could give it the lead in a key lung cancer indication.
Roche Tecentriq combo effective, but is it enough? pharmafile
December 11, 2017
When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-free survival in advanced NSCLC – the reaction was positive but it needs quantifying, by how much?
Roche’s Tecentriq approved for funding in UK in bladder cancer pharmafile
November 02, 2017
In a rare spot of good news for Tecentriq (atezolizumab), after a turbulent period, Roche’s drug has been given the nod by NICE to be funded through the Cancer Drug Fund (CDF).
Roche's Tecentriq scores approvals in metastatic lung and bladder cancer pharmafile
September 28, 2017
The decision in NSCLC was based on data generated from a Phase 2 and Phase 3 trial which demonstrated that Tecentriq enabled patients to live longer than those receiving docetaxel chemotherapy.
Roche receives EU approval of TECENTRIQ biospectrumasia
September 28, 2017
TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer (NSCLC).

Previous page 1 2 3 4 5 6 7 Next page